Retatrutide

Retatrutide is a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, primarily utilized by the community for weight management and appetite regulation. While clinical trials for obesity and type 2 diabetes are ongoing, users typically follow protocols ranging from 1 mg to 12 mg administered subcutaneously on a weekly basis. Readers should note that the current evidence base for off-label indications remains significantly thinner than the prevailing discourse suggests, as many exploratory applications lack published results. Reported side effects are infrequent, with occasional mentions of sleep disturbances, nausea, and fluid retention surfacing in community discussions.

Half-life~6 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.53.23.64.42.23.0

Research Evidence

Evidence shape

Retatrutide possesses moderate clinical evidence, primarily supported by human trials focused on obesity and type 2 diabetes. While the literature includes 18 published studies and 34 registered trials, only two trials have posted results, leaving the vast majority of the 15 mapped indications in exploratory or single-trial stages. Despite the presence of phase 3-grade research, the current evidence base remains narrow, with most clinical applications lacking the depth of multiple blinded, reported studies required to confirm efficacy across the broader range of investigated conditions.

Depthhow much
34 registered trials
22 completed · 2 with posted results · 11 recruiting / active · combined n=619
Breadthhow many areas
14 indications mapped
2 with results · 11 thin / exploratory · 1 animal-only · 7 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
2 blinded with results · AE rows aggregated from 2 trials · 10 linked publications on registered trials
Breadth and depth73 rows captured
Human
direct clinical signal
52
Animal
translational support
12
In vitro
mechanistic support
9
HighMediumLow

Anecdotal efficacy

Retatrutide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
BOC Peptide
--
1000 mg×10
$460.00
$0.46/mg
2
Bio Hack London
GB
100 mg
$79.19
$0.792/mg
3
Peptiology
GB
40 mg
$44.28
$1.101/mg
4
A1 Compounds
--
30 mg
$36.00
$1.2/mg
5
Mrbeetoe
--
50 mg
$75.00
$1.5/mg
6
Metbio Peptides
--
60 mg
$99.99
$1.67/mg

price offers can be sorted by column

1-6 of 314

RETATRUTIDE dosing & protocol

How RETATRUTIDE is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 39
Typical dose
12 mg1 mg – 12 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 12 reported doses · darker = more
Frequency
weekly
Route
subQ

In research trials, retatrutide was administered subcutaneously at doses ranging from 1 mg to 12 mg once weekly, with a typical dose of 12 mg per injection.

39 sources
Clinician practice
Doctor & published-protocol guidance · n = 4
Starting dose
1 mg1 mg – 12 mg
start
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 10 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
weekly
Route
subQ

Clinicians typically administer 12 mg subcutaneously once per week, according to sources, with reported use ranging from 1 mg to 12 mg weekly.

4 sources
Anecdotal
Community-reported real-world use · n = 204
Typical dose
1 mg200 µg – 43.5 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 253 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community reports most often cite a typical dose of 1 mg subcutaneously, with individual doses ranging from 200 µg to 43.5 mg; one source noted a weekly schedule of 1 mg/week, while the majority did not specify frequency or cycling.

204 sources

Related peptides

SemaglutideTirzepatideSurvodutideAOD-9604CagrilintideOrforglipronLiraglutideExenatideTesamorelinEloralintideTesofensineMazdutide